Overview

Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether intravenous Bortezomib combined with oral Panobinostat (LBH589) are effective in treating adult patients with relapsed/refractory peripheral T-cell lymphoma or NK/T-cell lymphoma after the failure of conventional chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Singapore General Hospital

Treatments:

Bortezomib
Histone Deacetylase Inhibitors
Panobinostat